81 results about "Hypoglycemic drugs" patented technology

The present application relates to the technical field of microbial medicine, and particularly to a preparation method and application of indole diterpenoid compounds. Specifically, the extract of plant endophytic fungus F4a after solid fermentation culture is separated and purified to obtain indole diterpenoid compounds; the plant endophytic fungus F4a is a strain with the preservation number CCTCC NO: M 2012531. The indole diterpenoid compounds provided by the present application have significant antifeedant, insecticidal and hypotensive activities, and they can be used as ideal candidate compounds of antifeedants, insecticides or hypoglycemic drugs. The compounds can be produced through fungal fermentation, and the preparation method is simple, efficient and high in product purity. The present application has good application prospect.

The application discloses a preparation method of ethanol extract of Drynaria Rhizome and application thereof. The method comprises the following steps: crushing and sieving Drynaria Rhizome, adding ethanol, reflux extraction, combining filtrates, vacuum concentration and drying, and thus the ethanol extract of Drynaria Rhizome is obtained. The in-vitro alpha-glucosidase enzyme inhibition experiment shows that the ethanol extract of Drynaria Rhizome has a significant inhibitory effect on alpha-glucosidase enzyme, and the IC 50 is about 142.68 μ g / mL. Therefore, the ethanol extract of Drynaria Rhizome can be used for preparing a hypoglycemic drug, health care product or functional food, and has a wide application prospect.

The invention discloses a procyanidine trimer compound, which has a chemical structure as shown in the specification. The hypoglycemic potential of the compound is evaluated through an in-vitro enzyme inhibition experiment, and the result shows that the compound has a remarkable inhibition effect on alpha-amylase, has good water solubility, is derived from natural plant resources, is clear in structure and good in safety, and has a huge application prospect in development of novel natural-source hypoglycemic drugs.

The invention provides corn stigma polysaccharide, a preparation method thereof and application of the corn stigma polysaccharide in preparation of hypoglycemic drugs, and belongs to the technical field of plant polysaccharide extraction. The preparation method comprises the following steps: mixing corn stigma powder, ascorbic acid and water, adding pectinase into the mixed solution to carry out first enzymolysis, and adding cellulase and papain after 20-30 minutes to carry out second enzymolysis; after enzymolysis is completed, protein in enzymatic hydrolysate is removed, a corn stigma polysaccharide extracting solution is obtained, the corn stigma polysaccharide extracting solution is concentrated under reduced pressure, absolute ethyl alcohol is added for alcohol precipitation, then dialysis is conducted, and the corn stigma polysaccharide is obtained. The corn stigma polysaccharide prepared by the method has high yield, purity and hypoglycemic activity, and can be applied to preparation of hypoglycemic drugs.

The application discloses corn silk glucan, a structure formula of which is [→4)-β-D-Glcp-(1→]n, wherein n is 6-60, and a molecular weight range is 1-9.8 kDa. By extracting effective components in corn silk, an extract is obtained, the extract is precipitated by 30-90% ethanol, corn silk crude polysaccharide is obtained, and after the corn silk crude polysaccharide is dissolved, the corn silk crude polysaccharide is sequentially subjected to biological membrane dialysis, ion exchange resin column and HPLC-ELSD separation and purification, and corn silk glucan is obtained. The corn silk glucan and zeaxanthin are compounded to form a glucan compound, the glucan compound can stabilize insulin and improve the activity of the insulin in mouse islet cells, and the glucan compound has 2-5 times stronger hypoglycemic activity than that of zeaxanthin alone, and therefore, the glucan compound has important significance for researching new hypoglycemic drugs or health-care food for assisting hypoglycemia.

This invention provides a mulberry leaf and wolfberry composition, comprising aqueous extracts of wolfberry, mulberry leaves, astragalus, yam, kudzu root, and green tea. This invention also provides oral preparations and food products containing this composition. Furthermore, this invention provides the application of the composition or oral preparation in the preparation of health foods that help maintain healthy blood sugar levels and hypoglycemic drugs. The composition provided by this invention has the effect of lowering blood sugar, and the selected raw materials are highly safe, have few toxic side effects, and are widely available, possessing significant market value and development prospects.

The present application relates to the technical field of medical devices, and particularly relates to a controlled release device, a preparation method thereof and an intelligent microneedle closed loop system. The controlled release device comprises a metal microneedle, a doped polypyrrole film coated on the surface of the metal microneedle and a drug loaded on the doped polypyrrole film. The controlled release device realizes the electrically controlled on-demand release of hypoglycemic drugs, and can make metformin release 41.1 mu g in 400 minutes, thereby providing a new possibility for personalized treatment of diabetes. Meanwhile, the present application also constructs an intelligent microneedle closed loop system by using a microneedle sensor, realizes real-time monitoring of blood glucose and linkage control of on-demand drug delivery, and can be continuously worn for seven days without tissue inflammation.

The present application relates to soybean active peptides with hypoglycemic activity and a preparation method and application thereof, and belongs to the technical field of active peptide proteins. The active peptides are selected from SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3 or SEQ ID NO.4; the amino acid sequences of the SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3 and SEQ ID NO.4 are respectively: GPFGT, DSRPLY, SGFGKL, IFGM. The soybean active peptides of the present application are verified by experiments to have hypoglycemic activity, are safe, have no toxic side effects, can be used as functional ingredients in hypoglycemic drugs, and have good potential and application prospects.

The present application relates to a kind of preparation methods of white birch alcohols-pectin nanoparticles loaded with peony polyphenol: 1) preparation peony polyphenol: 2) preparation pectin: 3) preparation white birch alcohols-pectin nanoparticles: white birch alcohols and peony seed pectin are dissolved in DMSO, N,N-dimethylaminopyridine is added as catalyst, reaction is carried out at room temperature for 8-16h, dialysis, freeze-drying is obtained white birch alcohols-pectin nanoparticles;4) white birch alcohols-pectin nanoparticles and peony polyphenol are dissolved in appropriate amount of DMSO according to proportion, then drop into distilled water under stirring, dialysis, freeze-drying, white birch alcohols-pectin nanoparticles loaded with peony polyphenol are obtained.The present application is connected by ester bond using carboxyl on pectin and hydroxyl on white birch alcohols, forms nano delivery carrier, then with peony polyphenol, forms water-soluble white birch alcohols-pectin / peony polyphenol nanoparticles, which can be used for preparing antitumor or hypoglycemic drug.

The invention belongs to the technical field of traditional Chinese medicine, and relates to polygonum cuspidatum homogeneous polysaccharide and a preparation method and application thereof.The polygonum cuspidatum homogeneous polysaccharide is mainly composed of galacturonic acid, rhamnose, galactose, glucuronic acid, glucose, mannose, xylose and glucuronide amine according to the molar ratio of 41.967: 24.624: 17.951: 5.427: 4.59: 3.501: 1.236: 0.358, and the weight-average molecular weight of the polygonum cuspidatum homogeneous polysaccharide is 26.57 kDa. The polygonum cuspidatum homogeneous polysaccharide is fixed in component, high in yield, good in hypoglycemic effect and good in safety, and a basis is provided for development of innovative hypoglycemic drugs.

The invention discloses a traditional Chinese medicine capsule for treating diabetes and a preparation method thereof, and belongs to the technical field of medicine preparation. The capsule is composed of main materials and auxiliary materials. The main materials are composed of 23-27 g of radix astragali, 23-27 g of radix puerariae, 18-22 g of rhizoma polygonati, 18-22 g of Chinese yam, 13-17 g of radix scrophulariae, 13-17 g of radix rehmanniae praeparata, 13-17 g of radix salviae miltiorrhizae, 8-12 g of rhizoma coptidis, 8-12 g of silkworm excrement, 8-12 g of rhizoma polygoni cuspidati, 7-9 g of liquorice and 5-7 g of fructus momordicae. The auxiliary material consists of lactose, microcrystalline cellulose and superfine silica powder in a mass ratio of 10: 10: 1, and the total weight of the auxiliary material is 210g. Double-section countercurrent extraction and low-temperature belt type drying are adopted, the retention rate of effective components is increased, the content of berberine and the content of salvianolic acid B are increased by 18% and 22% respectively, in addition, particle size grading compatibility is adopted, quick release and gastrointestinal tolerance are both considered, artificial sweeteners or chemical hypoglycemic drugs are not additionally added to the finished product, and the finished product conforms to human body metabolic motility.

The application provides a construction method of a cell model for screening hypoglycemic drugs, and belongs to the technical field of biotechnology.The method provided by the application comprises the following steps: cell verification, vector construction and plasmid extraction, cell electroporation, drug screening, stable strain amplification and Q-PCR verification.The application successfully constructs a stable fluorescence reporter model (Min6-ins2>EGFP) based on Min6 cells, and verifies the specificity and sensitivity of the model to insulin secretion promoting drugs through positive drug verification.The model is simple to operate, can be monitored in real time, is suitable for high-throughput screening, can be effectively used for hypoglycemic activity evaluation of complex components such as chemical drugs and traditional Chinese medicines, and provides a reliable tool for early screening of hypoglycemic drugs.

The application discloses a recombinant protein, a DNA fragment, an expression vector, a preparation method of a transgenic lettuce and an oral hypoglycemic drug, relates to the technical field of biological medicines, and the amino acid sequence of the recombinant protein is shown as SEQ ID NO:1.The recombinant protein, i.e., a human transferrin-proinsulin fusion protein, can utilize the natural combination of the human transferrin-transferrin receptor to mediate the endocytosis transport of proinsulin after being orally taken, pass through the intestinal tract to enter the blood system, and reduce blood sugar.According to animal experiments, the effect of the recombinant protein is close to that of natural insulin, and the recombinant protein realizes oral delivery of insulin.

The invention provides a preparation method and application of a chaenomeles speciosa leaf multi-effect refined extract. The method comprises the following steps: extracting with an ethanol solution, filtering, concentrating and drying to obtain the multiple-effect chaenomeles speciosa leaf fine extract. The refined extract has relatively strong antioxidant activity, antibacterial activity and hypoglycemic activity, and the antioxidant activity is three times that of vitamin C. The compound can be used for preparing antioxidative, antibacterial and hypoglycemic drugs. Or can be used for preparing wash supplies; or is used for preparing an external preparation for external antibiosis and anti-inflammation; or can be used for preparing food or medicine additives. The preparation technology of the refined extract is simple, safe and reliable, the prepared refined extract is high in yield, active ingredients are not prone to inactivation, and large-scale production is easy to expand.

The application belongs to the technical field of biological medicine, and discloses application of NP in preparation of a preparation for regulating metabolism of the intestines of senile type 2 diabetes. The NP is formed by hydrogen bond combination of a peptide from soft-shelled turtle eggs with naringenin in a mass ratio of 100:1, and the mass of the peptide is less than 3 kDa; the preparation is used for regulating phenotype-related metabolic modules and intestinal micro-ecological-related metabolic modules, remodeling the intestinal metabolic regulation network taking differential metabolites as a bridge, and thus systemically improving metabolic disorders related to senile type 2 diabetes. It is found that NP intervention can obviously correct abnormal total metabolic profiles of feces of senile type 2 diabetes mice, and make the disease type metabolic profile shift to a new steady state of intervention type. Non-targeted metabolomics analysis by LC-MS / MS shows that the overall metabolic profile of the high-dose NP group is closer to that of the classic hypoglycemic drug metformin group, indicating that NP has a significant metabolic remodeling capacity.

This invention discloses a method for establishing an improved mouse model of postprandial hypertriglyceridemia, belonging to the field of model construction technology. The key technical points are as follows: the method includes the following steps: obtaining a predetermined number of mouse models, which are then divided into a control group and a model group; administering gavage to both the model group and the control group for 120 minutes; sampling the mice in the model group and the control group after step S2, obtaining samples from both groups; and detecting glucose and lipid-related biochemical indicators, serum SOD, and MDA levels in the samples from both groups. In this invention, a mouse model of hypertriglyceridemia simulating the postprandial dietary state in humans is established through a combination of glucose and lipid administration via gavage. This will provide a research foundation for traditional Chinese medicine research on postprandial hypertriglyceridemia and related glucose and lipid metabolic diseases, and can also provide a model reference for the evaluation of lipid-lowering and hypoglycemic drugs and the development of health products.

The invention belongs to the technical field of biological medicine, and particularly relates to an alpha-amylase inhibitory active peptide and application thereof.The alpha-amylase inhibitory active peptide is separated from free peptide of smelly mandarin fish, and the amino acid sequence of the alpha-amylase inhibitory active peptide is shown as any one of Leuu-Pro-Lys-Leu-Arg-Val-Lys-Val; val-Glu-Lys-Ser-Lys-Val-Tyr is selected from the group consisting of Glu-Lys-Ser- Glu-Val-Ile-Glu-Leu-Asp-Trp-Arg is selected from the group consisting of Glu-Val-Ile-Glu- The active peptide has good alpha-amylase inhibitory activity, and can be applied to preparation of an alpha-amylase inhibitor, a hypoglycemic drug or a drug for preventing or treating hyperglycemia-related diseases.

The invention belongs to the technical field of biology, and discloses a combined preparation method of abalone viscera polysaccharide and polypeptide, an abalone viscera polysaccharide and polypeptide composition and application. According to the combined preparation method of the abalone viscera polysaccharide and polypeptide, a treatment process of combining staged enzymolysis and aspergillus oryzae fermentation is adopted, and all the steps jointly form an organic whole and cooperate with one another to degrade and modify substances contained in the abalone viscera; the abalone viscera polysaccharide polypeptide composition which has an excellent inhibition effect on alpha-glucosidase and DPP-IV is finally obtained, and the abalone viscera polysaccharide polypeptide composition has a good application prospect in development of hypoglycemic drugs and / or hypoglycemic functional foods.

This invention belongs to the field of biomedical technology and discloses the application of NP in the preparation of a glycemic regulator for aging type 2 diabetes. The NP is a nanoscale complex formed by hydrogen bonding of turtle egg peptide with a molecular weight less than 3 kDa and naringenin at a mass ratio of 100:1. The formulation promotes liver glycogen synthesis and repairs pancreatic tissue structure and pancreatic β-cell function by activating the hepatic IRS1 / PI3K / AKT / GSK-3β signaling pathway and upregulating GLUT2 protein expression. The NP provided by this invention can significantly reduce fasting blood glucose levels in aging type 2 diabetic mice, improve oral glucose tolerance, and reduce the area under the blood glucose curve. Simultaneously, by restoring insulin signal transduction, it significantly reduces the insulin resistance index and improves the insulin sensitivity index, with an improvement level approaching that of the classic hypoglycemic drug metformin.

The application discloses a kind of cyclopentapeptide compounds and its application in alpha-glycosidase inhibitor hypoglycemic drugs or preventive health products.The application provides a kind of marine fungi, name is Aspergillus sp.TW58-5, preservation number: GDMCC No:62093.The application utilizes the polarity difference of peptide compound to extract, separate and obtain a kind of cyclopentapeptide compound from the fermentation culture of marine fungi, the method is simple in operation, and the yield is high, and the product purity is high, suitable for large-scale production.Through in vitro alpha-glucosidase inhibitory activity evaluation, it shows that cyclopentapeptide compound has better alpha-glucosidase inhibitory activity, and the inhibition rate of alpha-glucosidase is 74%~100% at 400 μM concentration, which is stronger than positive drug acarbose, and can be used for preparing alpha-glucosidase inhibitor hypoglycemic drugs and preventive health food, with good development prospect.

This invention discloses the application of chestnut total burdock ethanol extract in the preparation of hypoglycemic drugs. In this invention, the chestnut total burdock ethanol extract with hypoglycemic effect is obtained by reflux extraction of chestnut total burdock with 70% ethanol. This extract can significantly inhibit the activity of α-glucosidase and has a significant inhibitory effect on postprandial blood glucose levels in T2DM model mice, exhibiting a significant hypoglycemic effect in vivo.

The invention relates to the technical field of gene drugs, in particular to buffalo milk protein peptide as well as a preparation method and application thereof, and mainly aims at determining the optimal hydrolysis condition for extracting antidiabetic protein hydrolysate from buffalo milk. In the hydrolysis process, several milk source raw materials of buffalo milk, namely freeze-dried skimmed milk, casein, whey protein and skimmed milk, are used, then the several raw materials are subjected to enzymolysis, and pepsin, alkaline protease and papain are respectively used as three enzymes for enzymolysis; by researching the optimal enzymolysis conditions, further analyzing enzymolysis products with alpha-glucosidase inhibition and recovering the enzymolysis products, several six protein peptides with alpha-glucosidase inhibition characteristics are obtained, and through protein structure analysis, the protein peptides have the alpha-glucosidase inhibition characteristics, have a good blood sugar reduction function and can be used for preparing the blood sugar-reducing peptide with the alpha-glucosidase inhibition characteristics. And a new raw material is provided for later preparation of hypoglycemic drugs or foods.

The invention discloses application of sitagliptin in preparation of a medicine for treating Graves eye diseases, and belongs to the field of biological medicine. The invention discloses the application of sitagliptin in preparation of the medicine for treating Graves eye diseases for the first time, and sitagliptin can improve expression of CD4 + CTL cytotoxic functional molecules and improve eye symptoms, extraocular muscle thickening and fibrosis, orbit fat neogenesis and orbit T lymphocyte infiltration of mice; the mouse spleen CD4 + CTL cell proportion is improved; in addition, the thyroid hormone level, thyroid hyperplasia and hypertrophy and lymphocyte infiltration of mice can be improved. Sitagliptin is a clinically common hypoglycemic drug, and is perfect in safety database, small in side effect and easy to popularize clinically. Therefore, the experimental result of the invention fully supports the new application of sitagliptin in treating Graves eye diseases, and is a new direction worthy of exploration for treating Graves eye diseases due to strong clinical operability.

The invention relates to a composition of a compound hypoglycemic drug and a preparation method of the composition, and relates to the technical field of pharmaceutical compositions. The composition of the compound hypoglycemic drug mainly comprises metformin hydrochloride and sitagliptin phosphate, a filling agent is microcrystalline cellulose and the like, a disintegrating agent is croscarmellose sodium and the like, a binding agent is povidone K30 and the like, a lubricating agent is sodium stearyl fumarate and the like, a wetting agent is lauryl sodium sulfate and the like, and a disintegrating agent is microcrystalline cellulose and the like. The sitagliptin metformin tablet is prepared by adopting a core-coated tablet preparation technology, firstly, sitagliptin is prepared into small tablets by adopting a powder direct compression process, metformin hydrochloride is prepared into particles by adopting a wet granulation process, then the small sitagliptin tablets are pressed into tablet cores to obtain finished tablets, and then the finished tablets are coated to obtain the sitagliptin metformin tablet. The preparation process can ensure the content uniformity of the product and improve the storage stability of the product.

The application discloses a full-closed-loop artificial pancreas medicine infusion control system, which comprises a program module, at least one detection module, a hypoglycemic medicine infusion module and a hyperglycemic medicine infusion module. An algorithm is preset in the program module, the detection module detects blood glucose values, the hypoglycemic medicine infusion module performs hypoglycemic medicine infusion according to infusion instructions calculated by the algorithm, the hyperglycemic medicine infusion module performs hyperglycemic medicine infusion according to infusion instructions calculated by the algorithm, and full-closed-loop control of artificial pancreas system medicine infusion is realized.

The invention discloses a novel BimBH3 mimic peptide analogue constructed on the basis of a nailing and fatty acid acylation dual-modification strategy and application of the novel BimBH3 mimic peptide analogue serving as a PTPN1 inhibitor to development of a long-acting hypoglycemic drug. The structural general formula of the BimBH3 mimic peptide analogue is as shown in a formula I. The structural general formula of the BimBH3 mimic peptide analogue is as shown in a formula I. The invention provides the BimBH3 mimic peptide analogue with a novel structure, and the BimBH3 mimic peptide analogue is constructed by adopting a nailing and fatty acid acylation dual-modification strategy and has the structural general formula as shown in the formula I. The invention further provides a preparation method of the BimBH3 mimic peptide analogue. On the basis of a BimBH3 functional domain core sequence, the novel BimBH3 mimic peptide analogue has target inhibitory activity, metabolic stability and in-vivo action durability through second-site lysine substitution, N-terminal palmitic acid conjugation and fifth, sixth and ninth site glutamic acid side chain mediated synthesis ring nailing modification, and the synthesis ring nailing mode is molecular lactam cyclization. Experiments show that the compound can efficiently inhibit PTPN1 activity, has a long-acting hypoglycemic effect in a type 2 diabetes animal model, and has the potential of being developed into a long-acting antidiabetic drug which is administered once a week. The invention also discloses a solid-phase synthesis preparation method of the compound and application of the compound as a potential PTPN1 inhibitor drug.

The application discloses application of calyculostero in preparation of blood sugar reducing drugs, and belongs to the technical field of pharmacological action of calyculostero. Experimental results show that the calyculostero can inhibit the activity of pancreatic alpha-amylase (IC50 is 4.34+ / -1.10 ug / mL) in a dose-dependent manner, reduce postprandial blood sugar, and improve sugar tolerance, reduce fasting blood sugar, improve total cholesterol and triglyceride levels, and reduce histopathological changes of liver, pancreas and kidney in long-term intervention, and has no obvious hepatotoxicity. The calyculostero can be used alone or together with a pharmaceutically acceptable excipient to prepare a pharmaceutical composition, and is used for reducing blood sugar or treating diabetes, and the dosage form includes oral preparations, injections and the like. The application provides a new natural medicine selection for drug treatment of diabetes.

The present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof, wherein R1 is selected from hydroxyl, R2 is selected from hydrogen and hydroxyl, R3 is selected from O-β-DGlc, O-β-DGlc-(2-1)-α-L-Rha, and methyl, R4 is selected from methyl, O-β-DGlc, and O-β-DGlc-(2-1)-α-L-Rha, R5 is selected from hydroxymethyl, hydrogen, and CH2O-β-DGlc, R6 is selected from methyl and hydroxymethyl, R7 is selected from methyl and hydroxymethyl, and R8 is selected from hydroxyl and O-β-DGlc-(2-1)-α-L-Rha. The beneficial effects of this invention are that it has obtained a new compound with α-glucosidase inhibitory activity that has not been reported in the literature, and the structure of the compound has been determined. The compound has good α-glucosidase inhibitory activity and can be formulated into a hypoglycemic drug suitable for clinical use. It can also be used as a lead compound for further research on its structure-activity relationship, to synthesize a series of hypoglycemic drugs and drug combinations. Furthermore, it can be used as an indicator component for the quality control of Hedyotis diffusa herbal material and its preparations, breaking through the current bottleneck in the research and development of Hedyotis diffusa.

The invention provides an application of a phenolic compound (3-mesoxy-5-pentylpheol) as shown in a formula I or pharmaceutically acceptable salt, ester and solvate of the phenolic compound in preparation of medicines or functional foods for reducing blood sugar and preventing and / or treating diabetes mellitus. The invention also provides a pharmaceutical composition which comprises the compound as shown in the formula I and pharmaceutically acceptable pharmaceutic adjuvants and is used as a pharmaceutical preparation, and the medicine is a hypoglycemic medicine and a medicine for preventing and / or treating diabetes mellitus as shown in the formula I.

The application discloses a Smad5 mutant and application thereof in preventing and treating diabetes.The amino acid sequence of the Smad5 mutant is shown as SEQ NO ID:1.The application further discloses a nucleic acid encoding the Smad5 mutant, a recombinant expression vector containing the nucleic acid and a transformant.The application also includes the application of the nucleic acid, the recombinant expression vector containing the nucleic acid and the transformant in preparing a medicine for preventing and / or treating diabetes.The Smad5 mutant can improve the symptoms of type 1 diabetes and type 2 diabetes in vivo, and has no toxic side effects compared with conventional oral hypoglycemic drugs, and has no damage to the liver and kidney of patients.In addition, an agent for regulating acid-base balance is disclosed, which comprises baking soda alkaline drinking water; the agent can reduce blood sugar and relieve the symptoms of diabetes, and is more economical and convenient to operate for patients.